CC-930

DRUG2 trials

Sponsors

Celgene

Conditions

Discoid LupusFibrosisIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseLung Diseases, InterstitialPulmonary Fibrosis

Phase 2

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

TerminatedNCT01203943

CelgeneFibrosis, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease +2

Start: 2011-01-01End: 2012-08-24Updated: 2019-11-19

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

TerminatedNCT01466725

CelgeneDiscoid Lupus

Start: 2011-11-01End: 2012-07-30Updated: 2019-11-19

Related Papers

JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers

Clinical and Translational Medicine2016-09-02118 citations